Heart Failure Market Epidemiology Report 2025-2035 | Drug Pipeline, Therapies, and Regional Outlook

According to the IMARC Group, the heart failure market size reached a value of USD 7.3 billion in 2024. Looking forward, the top 7 major markets are expected to reach USD 19.5 billion by 2035, exhibiting a growth rate (CAGR) of 9.42% during 2025-2035.

Heart failure is a severe and long-standing medical condition where the heart muscle can no longer pump enough blood and oxygen to accommodate the body's metabolic needs. This inefficiency tends to create a back-up of blood and the build-up of fluid in critical areas like the lungs, legs, and feet, which tends to present as shortness of breath and swelling. It is a progressive illness, i.e., its symptoms and severity gradually increase over the years, substantially reducing a patient's quality of life and overall long-term prognosis.  The market committed to treating heart failure is vast and complex.

It covers a wide range of solutions ranging from sophisticated diagnostic devices essential for timely and reliable detection to an ever-lengthening list of therapeutic medications intended to control symptoms and retard disease, new medical devices that can support or supplement cardiac function, and extensive supportive care services to enhance well-being of patients and help individuals and families deal with the intricacies of this complicated disease. One of the main challenges of heart failure management, with far-reaching consequences for the market, is that of "silent progression." Heart failure is often underdiagnosed, with symptoms persisting in many for five years or more before an official diagnosis can be made.  Even this is often only done when the patient arrives at hospital in a crisis.

This significant delay in diagnosis results in a more advanced presentation of the disease at diagnosis, preventing timely exposure to essential prevention therapies and thus elevating the rates of subsequent hospitalizations and adverse cardiovascular events. This point highlights a substantial need for enhanced early diagnostic capacity and proactive primary care approaches. These solutions are a significant, but perhaps underdeveloped, market potential for technologies that are able to recognize individuals who are at risk prior to the need for acute hospitalization, thus changing the model from reactive crisis management to proactive disease management. 

Request for a sample of this report: https://www.imarcgroup.com/heart-failure-market/requestsample

This report also provides a detailed analysis of the current heart failure marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Recent Developments:

• In April 2025, Mesoblast announced an update on its plans to meet with the U.S. FDA to discuss the accelerated approval pathway for Revascor (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction and inflammation.
• In December 2024, Cytokinetics disclosed that COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure), a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction, is open to enrollment.
• In May 2023, AstraZeneca announced that Farxiga (dapagliflozin) had been approved in the U.S. to reduce the risk of cardiovascular death, hospitalisation for heart failure and urgent heart failure (HF) visits in adults with HF. The approval by the FDA was based on positive results from the DELIVER Phase III trial.

Competitive Landscape with key players:

The competitive landscape of the heart failure market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Takeda
2. Novartis
3. Bayer HealthCare Pharmaceuticals/Merck & Co
4. AstraZeneca
5. Boehringer Ingelheim/Eli Lilly and Company
6. Janssen Pharmaceuticals
7. Cytokinetics
8. Mesoblast

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145